Lung Master Device for Lung Conditions

N/A

Recruiting

Led By Farahnaz Fallah Tafti, PhD

Research Sponsored by University of Nebraska

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Fall within the age ranges: 19-35 and above 65 years old

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and after one month of device use

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a device called The Lung Master to see if it can help people breathe better by increasing the amount of air their lungs can hold. The device is not yet approved by the FDA.

Who is the study for?

This trial is for individuals with breathing difficulties due to conditions like Asthma or COPD. Participants should be able to attend two study visits one month apart and use the Lung Master device daily, recording their usage in a diary.

What is being tested?

The trial is testing the Lung Master, an investigational device designed to increase lung capacity. It involves initial and follow-up spirometry tests one month apart to measure changes in lung volume after daily use of the device.

What are the potential side effects?

Since this trial involves a non-invasive pulmonary exerciser, side effects may include discomfort from regular use or fatigue during exercises. Specific side effects will depend on individual tolerance to respiratory training.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am either between 19-35 years old or older than 65.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and after one month of device use

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and after one month of device use

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and after one month of device use for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Inspiratory Capacity

Tidal Volume

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Lung Function in Young and Older AdultsExperimental Treatment1 Intervention

Lung functions will be assess for two groups: young and older adults. The age range of 19 to 35 is categorized as young adulthood. This age range was selected because the lungs mature around 19-25 years old. The age range above 65 is designated as late adulthood, where lung function gradually declines.

0 / 1Eligibility criteria met